Discovery of SCA-136, a novel 5-HT2C agonist, for the treatment of Schizophrenia

被引：0
|
作者：
Ramamoorthy, P. Siva
Beyer, Chad
Brennan, Julie
Dunlop, John
Gove, Stacey
Grauer, Steve
Harrison, Boyd L.
Lin, Qian
Malberg, Jessica
Marquis, Karen
Mazandarani, Hossein
Piesla, Mike
Pulicicchio, Claudine
Rosenzwieg-Lipson, Sharon
Sabb, Ann-Marie
Schechter, Lee
Stack, Gary
Zhang, Jean
机构：
[1] Wyeth Ayerst Res, Chem & Screening Sci, Princeton, NJ 08543 USA
[2] Wyeth Ayerst Res, Discovery Neurosci, Princeton, NJ 08543 USA
[3] Wyeth Ayerst Res, Neurosci, Princeton, NJ 08543 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2006年 / 231卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
21-MEDI
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Antipsychotic-like effects of SCA-136:: A novel 5-HT2C receptor agonist
    Marquis, KL
    Ator, N
    Dunlop, J
    Ramamoorthy, S
    Beyer, C
    Lin, Q
    Brennan, J
    Piesla, M
    Ashby, C
    Harrison, B
    Magolda, R
    Pangalos, MN
    Stack, G
    Rosenzweig-Lipson, S
    NEUROPSYCHOPHARMACOLOGY, 2005, 30 : S251 - S252
  • [2] Pharmacological characterization of the novel 5-HT2C agonist SCA-136:: Antidepressant-like effects
    Rosenzweig-Lipson, S
    Bergman, J
    Dunlop, J
    Marquis, K
    Zhang, J
    Ramamoorthy, S
    Malberg, J
    Pulicicchio, C
    Mazandarani, H
    Grauer, S
    Mitchell, PJ
    Harrison, B
    Pangalos, MN
    Schechter, L
    Stack, G
    NEUROPSYCHOPHARMACOLOGY, 2005, 30 : S188 - S188
  • [3] Characterization of Vabicaserin (SCA-136), a Selective 5-Hydroxytryptamine 2C Receptor Agonist
    Dunlop, John
    Watts, Stephanie W.
    Barrett, James E.
    Coupet, Joseph
    Harrison, Boyd
    Mazandarani, Hossein
    Nawoschik, Stanley
    Pangalos, Menelas N.
    Ramamoorthy, Siva
    Schechter, Lee
    Smith, Deborah
    Stack, Gary
    Zhang, Jean
    Zhang, Guoming
    Rosenzweig-Lipson, Sharon
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 337 (03): : 673 - 680
  • [4] Discovery of Lorcaserin: A selective 5-HT2C receptor agonist for the treatment of obesity
    Smith, Brian M.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [5] A 5-HT2C receptor agonist for the treatment of obesity?
    Van Baak, M
    Lentjes, M
    Mujakovic, S
    Slaap, B
    Saris, W
    OBESITY RESEARCH, 2003, 11 : A110 - A111
  • [6] Metformin and 5-HT2C Agonist Lorcaserin for Weight Loss in Schizophrenia
    Jarskog, Lars
    Stroup, T. Scott
    BIOLOGICAL PSYCHIATRY, 2018, 83 (09) : S105 - S106
  • [7] SAR of psilocybin analogs:: Discovery of a selective 5-HT2C agonist
    Sard, H
    Kumaran, G
    Morency, C
    Roth, BL
    Toth, BA
    He, P
    Shuster, L
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (20) : 4555 - 4559
  • [8] Sertindole is a serotonin 5-HT2c inverse agonist and decreases agonist but not antagonist binding to 5-HT2c receptors after chronic treatment
    Jarmo Hietala
    Mikko Kuoppamäki
    Hannu Majasuo
    Esa-Pekka Pälvimäki
    Aki Laakso
    Erkka Syvälahti
    Psychopharmacology, 2001, 157 : 180 - 187
  • [9] Sertindole is a serotonin 5-HT2c inverse agonist and decreases agonist but not antagonist binding to 5-HT2c receptors after chronic treatment
    Hietala, J
    Kuoppamäki, M
    Majasuo, H
    Pälvimäki, EP
    Laakso, A
    Syvälahti, E
    PSYCHOPHARMACOLOGY, 2001, 157 (02) : 180 - 187
  • [10] Serotonin 5-HT2C receptor homodimerization is not regulated by agonist or inverse agonist treatment
    Herrick-Davis, Katharine
    Grinde, Ellinor
    Weaver, Barbara A.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2007, 568 (1-3) : 45 - 53
12345